Notice: This company has been marked as potentially delisted and may not be actively trading. Novus Therapeutics (NVUS) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends NVUS vs. PULM, CARA, EQ, ENLV, LVTX, LPCN, SLGL, LGVN, DWTX, and NXTCShould you be buying Novus Therapeutics stock or one of its competitors? The main competitors of Novus Therapeutics include Pulmatrix (PULM), Cara Therapeutics (CARA), Equillium (EQ), Enlivex Therapeutics (ENLV), LAVA Therapeutics (LVTX), Lipocine (LPCN), Sol-Gel Technologies (SLGL), Longeveron (LGVN), Dogwood Therapeutics (DWTX), and NextCure (NXTC). These companies are all part of the "medical" sector. Novus Therapeutics vs. Pulmatrix Cara Therapeutics Equillium Enlivex Therapeutics LAVA Therapeutics Lipocine Sol-Gel Technologies Longeveron Dogwood Therapeutics NextCure Pulmatrix (NASDAQ:PULM) and Novus Therapeutics (NASDAQ:NVUS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, valuation, profitability, institutional ownership, risk, community ranking and earnings. Do institutionals & insiders have more ownership in PULM or NVUS? 11.8% of Pulmatrix shares are held by institutional investors. 0.6% of Pulmatrix shares are held by insiders. Comparatively, 2.2% of Novus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is PULM or NVUS more profitable? Novus Therapeutics has a net margin of 0.00% compared to Pulmatrix's net margin of -96.51%. Pulmatrix's return on equity of -45.97% beat Novus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Pulmatrix-96.51% -45.97% -30.72% Novus Therapeutics N/A -133.49%-30.52% Which has more risk and volatility, PULM or NVUS? Pulmatrix has a beta of 1.52, indicating that its stock price is 52% more volatile than the S&P 500. Comparatively, Novus Therapeutics has a beta of 2.07, indicating that its stock price is 107% more volatile than the S&P 500. Does the MarketBeat Community believe in PULM or NVUS? Novus Therapeutics received 56 more outperform votes than Pulmatrix when rated by MarketBeat users. Likewise, 66.84% of users gave Novus Therapeutics an outperform vote while only 48.28% of users gave Pulmatrix an outperform vote. CompanyUnderperformOutperformPulmatrixOutperform Votes19648.28% Underperform Votes21051.72% Novus TherapeuticsOutperform Votes25266.84% Underperform Votes12533.16% Which has higher earnings and valuation, PULM or NVUS? Pulmatrix has higher revenue and earnings than Novus Therapeutics. Pulmatrix is trading at a lower price-to-earnings ratio than Novus Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPulmatrix$7.30M3.85-$14.12M-$2.64-2.92Novus TherapeuticsN/AN/A-$16.01M-$21.58-0.21 Does the media refer more to PULM or NVUS? In the previous week, Pulmatrix had 4 more articles in the media than Novus Therapeutics. MarketBeat recorded 4 mentions for Pulmatrix and 0 mentions for Novus Therapeutics. Pulmatrix's average media sentiment score of 0.65 beat Novus Therapeutics' score of 0.00 indicating that Pulmatrix is being referred to more favorably in the media. Company Overall Sentiment Pulmatrix Positive Novus Therapeutics Neutral SummaryPulmatrix and Novus Therapeutics tied by winning 7 of the 14 factors compared between the two stocks. Get Novus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NVUS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NVUS vs. The Competition Export to ExcelMetricNovus TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.49M$6.86B$5.56B$9.10BDividend YieldN/A2.90%5.32%3.99%P/E Ratio-0.209.9790.3018.28Price / SalesN/A301.931,251.4080.65Price / CashN/A73.5045.9637.70Price / Book0.345.275.124.70Net Income-$16.01M$136.98M$111.33M$224.47M Novus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NVUSNovus TherapeuticsN/A$4.52-5.4%N/A+168.5%$6.49MN/A-0.207High Trading VolumePULMPulmatrix0.2115 of 5 stars$6.97-4.3%N/A+345.1%$25.44M$7.30M-2.6420Short Interest ↓News CoverageGap DownCARACara Therapeutics4.3471 of 5 stars$5.41-9.7%$27.84+414.6%-28.7%$24.72M$20.97M-0.2680Short Interest ↓Gap DownEQEquillium3.3165 of 5 stars$0.70+1.9%$5.00+616.9%-19.9%$24.71M$36.08M-4.9840Short Interest ↓ENLVEnlivex Therapeutics3.7666 of 5 stars$1.15-2.5%$9.50+726.1%-60.7%$24.62MN/A-1.1770Short Interest ↓Gap DownLVTXLAVA Therapeutics2.3311 of 5 stars$0.97+2.1%$3.33+243.6%-41.3%$24.59M$7.35M-0.9460Short Interest ↑Gap DownLPCNLipocine2.6522 of 5 stars$4.52-3.6%$10.00+121.2%+10.8%$24.18M$500,000.00-5.9510SLGLSol-Gel Technologies3.2389 of 5 stars$0.85-4.3%$5.00+489.6%-43.4%$23.63M$1.55M-2.4950Short Interest ↑LGVNLongeveron3.0946 of 5 stars$1.59-5.4%$8.67+445.1%-71.4%$23.59M$1.89M-0.2520News CoverageDWTXDogwood TherapeuticsN/A$17.40+52.6%N/AN/A$23.14MN/A-2.665NXTCNextCure4.6912 of 5 stars$0.81-1.3%$4.00+392.3%-34.0%$22.76MN/A-0.3990Short Interest ↓ Related Companies and Tools Related Companies PULM Alternatives CARA Alternatives EQ Alternatives ENLV Alternatives LVTX Alternatives LPCN Alternatives SLGL Alternatives LGVN Alternatives DWTX Alternatives NXTC Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NVUS) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredElon’s ultimate power move?THE ELON SHOCK All of Elon Musk’s strange behavior may soon make sense… and impact the markets in a way no ...Altimetry | SponsoredNew catalyst on Wall Street’s radar for this week (NOT Trump)Wall Street is already looking past Trump… To a new catalyst on the near horizon that could be even bigger ...Timothy Sykes | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Novus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NVUS Stock Alerts